Ampersand Biosciences awarded contract by NIAID for further characterization and validation of monoclonal antibodies to study respiratory

Ampersand Biosciences was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) on September 30, 2024 until September 29, 2026 to further characterize and validate monoclonal antibodies to study respiratory.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: AN12 – Health R&D Services; Health Care Services; Applied Research